Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.45 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.45 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12926063 | 0.82 | NPSR1 (0.45) | ALDH1A1CYP1A2CYP2C19SMN1; SMN2RXFP1 | |
| SCHEMBL12926064 | 0.82 | NPSR1 (0.45) | ALDH1A1CYP1A2CYP2C19SMN1; SMN2RXFP1 | |
| SCHEMBL18722036 | 0.81 | NPSR1 (0.43) | ALDH1A1CYP1A2CYP2C19SMN1; SMN2RXFP1 | |
| SCHEMBL5121155 | 0.77 | HPGD (0.50) | ALDH1A1CYP1A2CYP2C19SMN1; SMN2RXFP1 | |
| SCHEMBL27042715 | 0.75 | ALDH1A1 (0.40) | ALDH1A1CYP1A2CYP2C19SMN1; SMN2RXFP1 | |
| SCHEMBL27064658 | 0.75 | NPSR1 (0.38) | ALDH1A1CYP1A2CYP2C19SMN1; SMN2RXFP1 | |
| SCHEMBL27042595 | 0.75 | SLC6A3 (0.39) | ALDH1A1CYP1A2CYP2C19SMN1; SMN2RXFP1 | |
| SCHEMBL27042813 | 0.75 | NPSR1 (0.38) | ALDH1A1CYP1A2CYP2C19SMN1; SMN2RXFP1 | |
| SCHEMBL5119543 | 0.74 | ALDH1A1 (0.42) | ALDH1A1CYP1A2CYP2C19SMN1; SMN2RXFP1 | |
| SCHEMBL6112098 | 0.74 | HPGD (0.52) | ALDH1A1CYP1A2CYP2C19SMN1; SMN2RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028335-A1 | NOVEL ISOTHIAZOL-3-YL AND ISOXAZOL-3-YL SULFONAMIDE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4558497-A1 | NOVEL ISOTHIAZOL-3-YL AND ISOXAZOL-3-YL SULFONAMIDE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2025-05-28 | — | — | EP | disclosed |
| WO-2024017855-A1 | NOVEL ISOTHIAZOL-3-YL AND ISOXAZOL-3-YL SULFONAMIDE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-01-25 | — | — | WO | disclosed |
| WO-2024017855-A1 | NOVEL ISOTHIAZOL-3-YL AND ISOXAZOL-3-YL SULFONAMIDE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-01-25 | — | — | WO | disclosed |
| US-10208068-B2 | Macrocycles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180148461-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-31 | — | — | US | disclosed |
| US-9975910-B2 | Hetero-fused cyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-05-22 | — | — | US | disclosed |
| US-9975910-B2 | Hetero-fused cyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-05-22 | — | — | US | disclosed |
| US-9975910-B2 | Hetero-fused cyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-05-22 | — | — | US | disclosed |
| US-9902742-B2 | Macrocycles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
| EP-2739628-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2014-06-11 | — | — | EP | disclosed |
| WO-2013022818-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-14 | — | — | WO | disclosed |
| EP-2094658-B1 | TETRAHYDROCYCLOPENTA[B]INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | LILLY CO ELI (US) | 2011-12-21 | — | — | EP | disclosed |
| US-7968587-B2 | Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators | ELI LILLY AND COMPANY (US) | 2011-06-28 | — | — | US | disclosed |
| US-7868014-B2 | 1-(hetero)aryl-3-amino-pyrrolidine derivatives for use as mGluR3 antagonists | ELI LILLY AND COMPANY (US) | 2011-01-11 | — | — | US | disclosed |
| US-20100069404-A1 | TETRAHYDROCYCLOPENTA[b] INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY | 2010-03-18 | — | — | US | disclosed |
| EP-1805165-B1 | 1-(HETERO)ARYL-3-AMINO-PYRROLIDINE DERIVATIVES FOR USE AS MGLUR3 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2009-12-16 | — | — | EP | disclosed |
| EP-2094658-A2 | TETRAHYDROCYCLOPENTA[B]INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2009-09-02 | — | — | EP | disclosed |
| US-20080300266-A1 | 1-(Hetero)Aryl-3-Amino-Pyrrolidine Derivatives for Use as Mglur3 Antagonists | ELI LILLY AND COMPANY (US) | 2008-12-04 | — | — | US | disclosed |
| WO-2008063867-A2 | TETRAHYDROCYCLOPENTA[B] INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148461-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F12 | ALDH1A1 4457/4885CYP1A2 1559/4885CYP2C19 882/4885 |
| US-10208068-B2 | Macrocycles as factor XIa inhibitors | TFPI, TFPI2, F12 | ALDH1A1 4479/4885CYP1A2 1285/4885CYP2C19 732/4885 |
| US-20260028335-A1 | NOVEL ISOTHIAZOL-3-YL AND ISOXAZOL-3-YL SULFONAMIDE COMPOUNDS | GPR180, GPR27, GPR65 | ALDH1A1 873/4885CYP1A2 2964/4885CYP2C19 3106/4885 |
| US-20100069404-A1 | TETRAHYDROCYCLOPENTA[b] INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, NR5A1, MUSK | ALDH1A1 3343/4885CYP1A2 460/4885CYP2C19 525/4885 |
| US-20080300266-A1 | 1-(Hetero)Aryl-3-Amino-Pyrrolidine Derivatives for Use as Mglur3 Antagonists | GRM3, GRM1, GRIA3 | ALDH1A1 3907/4885CYP1A2 1956/4885CYP2C19 1279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.